Product nameKAT13C / NCOA2 peptide
See all KAT13C / NCOA2 proteins and peptides
Our Abpromise guarantee covers the use of ab4917 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
This peptide may be used for neutralization and control experiments with the polyclonal antibody that reacts with this product and GRIP1, catalog ab2842. Using a solution of peptide of equal volume and concentration to the corresponding antibody will yield a large molar excess of peptide (~ 70-fold) for competitive inhibition of antibody-protein binding reactions.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
- Class E basic helix-loop-helix protein 75
- glucocorticoid receptor interacting protein 1
FunctionTranscriptional coactivator for steroid receptors and nuclear receptors. Coactivator of the steroid binding domain (AF-2) but not of the modulating N-terminal domain (AF-1). Required with NCOA1 to control energy balance between white and brown adipose tissues.
Involvement in diseaseNote=Chromosomal aberrations involving NCOA2 may be a cause of acute myeloid leukemias. Inversion inv(8)(p11;q13) generates the KAT6A-NCOA2 oncogene, which consists of the N-terminal part of KAT6A and the C-terminal part of NCOA2/TIF2. KAT6A-NCOA2 binds to CREBBP and disrupts its function in transcription activation.
Sequence similaritiesBelongs to the SRC/p160 nuclear receptor coactivator family.
Contains 1 bHLH (basic helix-loop-helix) domain.
Contains 1 PAS (PER-ARNT-SIM) domain.
DomainContains four Leu-Xaa-Xaa-Leu-Leu (LXXLL) motifs. The LXXLL motifs are essential for the association with nuclear receptors and are, at least in part, functionally redundant.
The LLXXLXXXL motif is involved in transcriptional coactivation and CREBBP/CBP binding.
Contains 2 C-terminal transcription activation domains (AD1 and AD2) that can function independently.
modificationsPhosphorylated upon DNA damage, probably by ATM or ATR.
- Information by UniProt
ab4917 has not yet been referenced specifically in any publications.